Eisai Inc recently announced plans for a new pharmaceutical production and formulation research and development facility for parenteral or intravenous oncology treatments. The company expects ground breaking for the new facility in the fall of 2006. Completion is anticipated in 3 years,with operations beginning in 2009. Eisai has a number of drugs in the pipeline for patients with cancer.
"Oncology is one of Eisai's long-standing therapeutic areas of focus, supporting our human health care mission to increase benefits to patients and their families and satisfy unmet medical needs," said Lonnel Coats, president and chief operating officer for Eisai Inc.
The $90-million, approximately 65,000-sq-ft facility will be located in Research Triangle Park, NC. The building will encompass aseptic processing suites, laboratories, and other support functions. A separate $15- million central utilities building also is planned to supply power, steam, chilled water, and compressed air to the existing operations and the new parenteral facility.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs